North America: Largest market, powered by high drug consumption, strong regulatory frameworks, and advanced biotech manufacturing infrastructure. Asia Pacific: Fastest-growing, led by India's contract ...

C2 Pharma, which concentrates on hard-to-make ingredients, has picked up a new supply of digoxin. The deal will give it two supplies of API for making the sometimes-difficult-to-get drug. The ...

Destination Germany is the watchword for those in the international cannabis industry—but it is still a rocky path to gaining access for most. Specifically, there is a lot of confusion surrounding API ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active ...

BOCA RATON, Fla.--(BUSINESS WIRE)--LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product life cycle, today reported that its unique mix of active pharmaceutical ...

The FDA, disappointed in the manufacturing methods it saw at a Chinese API maker’s facility during a fall inspection, first put Sichuan Friendly Pharmaceutical on its import alert list and has now ...

Teva CEO Richard Francis expressed confidence that the API business could grow more than its current 6% annual rate. The CEO also assured that future M&A activities would be approached thoughtfully ...

C2 PHARMA, the global leader in ophthalmic APIs announces the launch of its latest API, timolol maleate. The validation campaign for timolol maleate was completed in August 2025, and a Certificate of ...